D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 129 SEK -1.9% Market Closed
Market Cap: 2.1B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Devyser Diagnostics AB
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Devyser Diagnostics AB
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
D
Devyser Diagnostics AB
STO:DVYSR
Total Receivables
kr45.3m
CAGR 3-Years
22%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Total Receivables
kr133.9m
CAGR 3-Years
-2%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Total Receivables
kr224.6m
CAGR 3-Years
70%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Total Receivables
kr708m
CAGR 3-Years
44%
CAGR 5-Years
23%
CAGR 10-Years
25%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Total Receivables
kr8.1B
CAGR 3-Years
27%
CAGR 5-Years
24%
CAGR 10-Years
29%
BioArctic AB
STO:BIOA B
Total Receivables
kr7.1m
CAGR 3-Years
8%
CAGR 5-Years
13%
CAGR 10-Years
N/A
No Stocks Found

Devyser Diagnostics AB
Glance View

Market Cap
2.1B SEK
Industry
Biotechnology

Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.

DVYSR Intrinsic Value
124.21 SEK
Overvaluation 4%
Intrinsic Value
Price
D

See Also

What is Devyser Diagnostics AB's Total Receivables?
Total Receivables
45.3m SEK

Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Total Receivables amounts to 45.3m SEK.

What is Devyser Diagnostics AB's Total Receivables growth rate?
Total Receivables CAGR 5Y
24%

Over the last year, the Total Receivables growth was 36%. The average annual Total Receivables growth rates for Devyser Diagnostics AB have been 22% over the past three years , 24% over the past five years .

Back to Top